11 results about "Reproductive system disease" patented technology

The invention relates to the technical field of biomedical treatment, in particular to bifidobacterium longum subsp. Longum and application thereof in drugs related to reproductive system diseases. The invention provides a strain of Bifidobacterium longum subsp. Longum NCU-06, which is preserved in China General Microbiological Culture Collection Center (CGMCC), the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, the preservation date is January 18, 2023, and the preservation number is CGMCC No.26491. The invention also provides a method for preparing the Bifidobacterium longum subsp. Longum NCU-06. The bifidobacterium longum subsp. Longum NCU-06 has a treatment effect on various female reproductive system diseases, for example, the bifidobacterium longum subsp. Longum NCU-06 can be used for treating endometriosis, ovarian cancer, ovarian cancer parneoplastic thrombocythemia and ovarian hyperstimulation syndrome.

The current invention is in the field of molecular biology / pharmacology and provides novel 3-oxabicyclo[3.3.1]nonene compounds and derivatives that modulate the effects of the classical estrogen receptors alpha and beta (ERalpha and ERbeta) with little to no biological or physiological effects on the G protein-coupled estrogen receptor GPER (also known as GPR30). These compounds may function as agonists and / or antagonists of one or more of the disclosed classical estrogen receptors. Diseases that are mediated through one or more of these receptors include cancer (including but not limited to breast (particularly endocrine or anti-hormone resistant, and for the prevention / reduction of endocrine or anti-hormone resistance), reproductive and other hormone-dependent cancers, leukemia, colon cancer, prostate cancer), reproductive (genito-urological) including endometritis, prostatitis, polycystic ovarian syndrome, bladder control, hormone-related disorders, hearing disorders, cardiovascular conditions including hot flashes and profuse sweating, hypertension, stroke, obesity, osteoporosis, hematologic diseases, vascular diseases or conditions such as venous thrombosis, atherosclerosis, among numerous others and disorders of the central and peripheral nervous system, including depression, insomnia, anxiety, multiple sclerosis, neuropathy, neurodegenerative disorders (such as Parkinson's disease and Alzheimer's disease), as well as inflammatory bowel disease, Crohn's disease, coeliac (celiac) disease and related disorders of the intestine, among numerous others as described herein. A contraceptive indication to prevent or reduce the likelihood of pregnancy after intercourse is a further aspect of the present invention.

The present application relates to a kind of SGLT2 inhibitor in the preparation for treating hormone receptor low reaction type reproductive system disease in the application of drug, in particular, SGLT2 inhibitor and hormone can improve or enhance the sensitivity and / or for reversing the drug resistance of endocrine therapy drug, such as hormone, can enhance the therapeutic effect of such drug, especially in drug-resistant reproductive system disease and tumor treatment has good application prospect.

The subject of the application is a dietary supplement containing 2.5 - 7 wt.% indole-3-carbinol, 2 - 6 wt.% epigallocatechin gallate, 30 - 70 wt.% myo-inositol, 6 - 12.5 wt.% N-acetylcysteine, 2.5 - 7 wt.% quercetin, 5 - 8.5 wt.% Omega-3 acid, 5 - 8.5 wt.% alphalipoic acid, 2 - 6 wt.% vitamin C, 1 - 5 wt.% resveratrol, 0.01 - 0.2 wt.% vitamin D3, 0.5 - 3.5 wt.% vitamin E, 0.2 - 15 wt.% alpha-lactalbumin, 0.04 - 20 wt.% curcumin, 0.2 – 15% w / w D-chiroinositol, 0.2- 24% w / w inulin, a probiotic consisting of a mixture of strains of the Lactobacillus, Bifidobacterium and Saccharomyces genera for patients with reproductive system diseases supporting the reduction of estrogen levels and estrogen and progesterone receptors.

The invention discloses a method for analyzing the pharmacodynamic material basis and action mechanism of a laying hen Bao traditional Chinese medicine. The method specifically comprises the following steps: (1) identifying chemical components in the laying hen Bao by UHPLC-HRMS (Ultra High Performance Liquid Chromatography-High Resolution Mass Spectrometry); (2) screening a core target spot of the laying hen for treating poultry reproductive system diseases; (3) obtaining the drug effect material basis of the laying hen feed; and (4) constructing a'laying hen bao-effective component-core target group-signal channel 'regulation network. According to the method, a traditional Chinese medicine component chemical analysis technology and a network pharmacology method are combined, a systematic and multi-dimensional analysis tool is provided for research on the traditional Chinese medicine effect material basis of the traditional Chinese medicine compound laying hen Bao, the chemical components in the traditional Chinese medicine compound laying hen Bao can be effectively recognized, the medicine effect material basis can be screened, target spots and channels related to the medicine effect can be recognized, and the method is suitable for popularization and application. A new thought is provided for revealing the scientific connotation of'multi-component, multi-target and multi-channel 'of the traditional Chinese medicine compound laying hen bao.

This invention provides 3-amino-4-(piperazin-1-yl)benzamide derivatives, pharmaceutical compositions comprising them, methods for their preparation, and applications. These compounds act as PLAGL2 protein inhibitors, playing a significant role in various diseases, including but not limited to pain, inflammation, immune dysfunction, neurological and psychiatric disorders, respiratory diseases, urinary system diseases, reproductive system diseases, embryonic developmental abnormalities, cell metabolic disorders, differentiation problems, and viral infections. PLAGL2 plays a particularly positive role in the occurrence, development, and prognosis of malignant tumors such as liver cancer, lung cancer, and glioma. The compounds of this invention exhibit excellent PLAGL2 inhibitory activity. This invention also provides the compounds comprising the pharmaceutically acceptable salts thereof, pharmaceutically acceptable carriers or excipients, and methods for their preparation.

The invention relates to the technical field of medical apparatus and instruments, in particular to a device for assisting use of external medicine. The cup stand is in a prismatic table shape, a cup groove is formed in the top of the cup stand and used for containing the medicine soaking cup, and an opening is formed in the bottom of the cup stand. The clamping assembly at the top of the cup stand comprises a fixing plate, a clamping plate and a spring, and an anti-sliding rubber strip is arranged on the inner wall of the clamping plate and can stabilize the medicine soaking cup; the bottom fixing assembly is composed of a bottom pad and a suction valve, and the bottom pad is provided with anti-skid grains so that the device can be stably adsorbed on a plane; a collecting ring of the middle anti-spilling assembly is provided with a waste liquid collecting groove, and overflowing liquid medicine can be intercepted. The device is simple in structure, can be independently operated by a patient, does not need the assistance of other people, reduces the nursing burden, is convenient to clean and replace parts, can effectively prevent the device from toppling over and liquid medicine from spilling and leaking, is suitable for adjuvant therapy of various reproductive system diseases, and has portability and practicability.

The present invention relates to bacteria and metabolites thereof that are capable of binding to vaginal cells and producing hydrogen peroxide, their use in probiotic compositions and food products and methods for their selection. The invention also relates to the use of said bacteria, metabolites and probiotic compositions for the prevention and / or treatment of urogenital disorders.

The present application relates to the field of biological medical technology, and in particular to Bifidobacterium longum subsp. longum and its application in drugs related to reproductive system diseases. Bifidobacterium longum subsp. longum The present application provides a Bifidobacterium longum subsp. longum (NCU-06) strain, which has been preserved in the China General Microbiological Culture Collection Center, located at No. 1, Yihuangyuan 3rd, Beichen West Road, Chaoyang District, Beijing, on January 18, 2023, and the preservation number is CGMCC No. 26491. The above-mentioned Bifidobacterium longum subsp. longum NCU-06 has a therapeutic effect on various female reproductive system diseases, for example, it can be used to treat endometriosis, ovarian cancer, paraneoplastic thrombocytosis of ovarian cancer, and ovarian hyperstimulation syndrome.

The invention belongs to the technical field of medicines, and particularly relates to application of lactobacillus gasseri in preparation of a medicine for improving salpingitis and intestinal health of laying hens. The lactobacillus gasseri is a lactobacillus gasseri bacterial strain BNCC339385, and the lactobacillus gasseri is a lactobacillus gasseri bacterial strain The application effect of the lactobacillus gasseri in improving the fallopian tube inflammation injury of the laying hens is reported for the first time; in addition, the potential mechanism of improving the reproductive tract inflammation by inhibiting the PI3K / AKT signal channel of the lactobacillus gasseri is verified on the molecular level. The invention aims to explore the effect of lactobacillus gasseri on relieving female reproductive system diseases by taking laying hens as research objects, provides a new application of lactobacillus gasseri in improving intestinal health of laying hens and related products of fallopian tube inflammation, and expands the related research of probiotics on relieving intestinal health of laying hens and reproductive system diseases.

This application discloses the use of naphthalene ring-based low-molecular-weight compounds. This application is the first to discover that compounds represented by general formula I have excellent therapeutic effects against various intractable diseases, including reproductive system diseases, autoimmune diseases, skin diseases, eye diseases, muscle or bone degenerative diseases, neurological diseases, anemia, adrenal diseases, chronic gastritis, myocarditis, periodontitis, hypothyroidism, alopecia, liver damage, tinnitus, and chronic obstructive pulmonary disease. Therefore, this has extremely great application value in the prevention and treatment of the aforementioned diseases.